Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.71 |
| ▸ | F3 | P13726 | 1/20 | 0.71 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | GABRP | O00591 | 4/20 | 0.56 |
| ▸ | GABRD | O14764 | 4/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.56 |
| ▸ | GABRE | P78334 | 4/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.56 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.56 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.56 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.56 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716737 | 0.87 | NR4A2 (0.61) | F7F3NR4A2GABRPGABRD | |
| SCHEMBL3590666 | 0.87 | F7 (0.75) | F7F3NR4A2GABRPGABRD | |
| SCHEMBL2535532 | 0.85 | F7 (0.73) | F7F3NR4A2GABRPGABRD | |
| SCHEMBL1434913 | 0.83 | F7 (1.00) | F7F3NR4A2GABRPGABRD | |
| SCHEMBL592274 | 0.81 | F7 (0.77) | F7F3NR4A2GABRPGABRD | |
| SCHEMBL31748335 | 0.81 | NR4A2 (0.61) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL21366320 | 0.81 | KDM4E (0.59) | F7F3CDK4CCND1 | |
| SCHEMBL3725153 | 0.81 | NR4A2 (0.63) | F7F3NR4A2CDK4CCND1 | |
| SCHEMBL13013297 | 0.80 | NR4A2 (0.74) | F7F3NR4A2GABRPGABRD | |
| SCHEMBL5912617 | 0.80 | F7 (0.75) | F7F3NR4A2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1859798-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2015-12-30 | — | — | EP | disclosed |
| US-8044090-B2 | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2010139982-A1 | INDOLE DERIVATIVES FOR THE STIMULATION OF STEM CELL PROLIFERATION | THE UNIVERSITY OF SHEFFIELD (GB) | 2010-12-09 | — | — | WO | disclosed |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2009-12-10 | — | — | US | disclosed |
| EP-1859798-A1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1379239-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| CN-1610547-A | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | LILLY CO ELI (US) | 2005-04-27 | — | — | CN | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | F7 2658/4885F3 4253/4885NR4A2 839/4885 |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | F7 2658/4885F3 4253/4885NR4A2 839/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | F7 2658/4885F3 4253/4885NR4A2 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.